Literature DB >> 21344539

COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta.

Katarina Lindahl1, Aileen M Barnes, Nadja Fratzl-Zelman, Michael P Whyte, Theresa E Hefferan, Elena Makareeva, Marina Brusel, Michael J Yaszemski, Carl-Johan Rubin, Andreas Kindmark, Paul Roschger, Klaus Klaushofer, William H McAlister, Steven Mumm, Sergey Leikin, Efrat Kessler, Adele L Boskey, Osten Ljunggren, Joan C Marini.   

Abstract

Osteogenesis imperfecta (OI) is most often caused by mutations in the type I procollagen genes (COL1A1/COL1A2). We identified two children with substitutions in the type I procollagen C-propeptide cleavage site, which disrupt a unique processing step in collagen maturation and define a novel phenotype within OI. The patients have mild OI caused by mutations in COL1A1 (Patient 1: p.Asp1219Asn) or COL1A2 (Patient 2: p.Ala1119Thr), respectively. Patient 1 L1-L4 DXA Z-score was +3.9 and pQCT vBMD was+3.1; Patient 2 had L1-L4 DXA Z-score of 0.0 and pQCT vBMD of -1.8. Patient BMD contrasts with radiographic osteopenia and histomorphometry without osteosclerosis. Mutant procollagen processing is impaired in pericellular and in vitro assays. Patient dermal collagen fibrils have irregular borders. Incorporation of pC-collagen into matrix leads to increased bone mineralization. FTIR imaging confirms elevated mineral/matrix ratios in both patients, along with increased collagen maturation in trabecular bone, compared to normal or OI controls. Bone mineralization density distribution revealed a marked shift toward increased mineralization density for both patients. Patient 1 has areas of higher and lower bone mineralization than controls; Patient 2's bone matrix has a mineral content exceeding even classical OI bone. These patients define a new phenotype of high BMD OI and demonstrate that procollagen C-propeptide cleavage is crucial to normal bone mineralization.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21344539      PMCID: PMC3103631          DOI: 10.1002/humu.21475

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  37 in total

1.  Ehlers-Danlos syndrome type VIIA and VIIB result from splice-junction mutations or genomic deletions that involve exon 6 in the COL1A1 and COL1A2 genes of type I collagen.

Authors:  P H Byers; M Duvic; M Atkinson; M Robinow; L T Smith; S M Krane; M T Greally; M Ludman; R Matalon; S Pauker; D Quanbeck; U Schwarze
Journal:  Am J Med Genet       Date:  1997-10-03

2.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

3.  Bone morphogenetic protein-1: the type I procollagen C-proteinase.

Authors:  E Kessler; K Takahara; L Biniaminov; M Brusel; D S Greenspan
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

4.  Mutations in the carboxyl-terminal propeptide of the pro alpha 1(I) chain of type I collagen result in defective chain association and produce lethal osteogenesis imperfecta.

Authors:  S D Chessler; G A Wallis; P H Byers
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

5.  Constant mineralization density distribution in cancellous human bone.

Authors:  P Roschger; H S Gupta; A Berzlanovich; G Ittner; D W Dempster; P Fratzl; F Cosman; M Parisien; R Lindsay; J W Nieves; K Klaushofer
Journal:  Bone       Date:  2003-03       Impact factor: 4.398

6.  Partial purification and characterization of a procollagen C-proteinase from the culture medium of mouse fibroblasts.

Authors:  E Kessler; R Adar; B Goldberg; R Niece
Journal:  Coll Relat Res       Date:  1986-07

7.  The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1.

Authors:  S W Li; A L Sieron; A Fertala; Y Hojima; W V Arnold; D J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

8.  Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies.

Authors:  P Roschger; P Fratzl; J Eschberger; K Klaushofer
Journal:  Bone       Date:  1998-10       Impact factor: 4.398

9.  Use of Bmp1/Tll1 doubly homozygous null mice and proteomics to identify and validate in vivo substrates of bone morphogenetic protein 1/tolloid-like metalloproteinases.

Authors:  William N Pappano; Barry M Steiglitz; Ian C Scott; Douglas R Keene; Daniel S Greenspan
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

10.  Failure of ventral body wall closure in mouse embryos lacking a procollagen C-proteinase encoded by Bmp1, a mammalian gene related to Drosophila tolloid.

Authors:  N Suzuki; P A Labosky; Y Furuta; L Hargett; R Dunn; A B Fogo; K Takahara; D M Peters; D S Greenspan; B L Hogan
Journal:  Development       Date:  1996-11       Impact factor: 6.868

View more
  48 in total

Review 1.  Metalloproteinases in Drosophila to humans that are central players in developmental processes.

Authors:  Alison Muir; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 2.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

3.  Fourier transform infrared spectroscopic imaging parameters describing acid phosphate substitution in biologic hydroxyapatite.

Authors:  Lyudmila Spevak; Carol R Flach; Tracey Hunter; Richard Mendelsohn; Adele Boskey
Journal:  Calcif Tissue Int       Date:  2013-02-05       Impact factor: 4.333

4.  Peptidyl 3-hydroxyproline binding properties of type I collagen suggest a function in fibril supramolecular assembly.

Authors:  David M Hudson; Lammy S Kim; MaryAnn Weis; Daniel H Cohn; David R Eyre
Journal:  Biochemistry       Date:  2012-03-15       Impact factor: 3.162

Review 5.  Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation.

Authors:  Joan C Marini; Adi Reich; Simone M Smith
Journal:  Curr Opin Pediatr       Date:  2014-08       Impact factor: 2.856

Review 6.  Bone composition: relationship to bone fragility and antiosteoporotic drug effects.

Authors:  Adele L Boskey
Journal:  Bonekey Rep       Date:  2013-12-04

7.  A novel COL1A2 C-propeptide cleavage site mutation causing high bone mass osteogenesis imperfecta with a regional distribution pattern.

Authors:  T Rolvien; U Kornak; J Stürznickel; T Schinke; M Amling; S Mundlos; R Oheim
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

8.  Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice.

Authors:  Alison M Muir; Yinshi Ren; Delana Hopkins Butz; Nicholas A Davis; Robert D Blank; David E Birk; Se-Jin Lee; David Rowe; Jian Q Feng; Daniel S Greenspan
Journal:  Hum Mol Genet       Date:  2014-01-12       Impact factor: 6.150

9.  Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta.

Authors:  Víctor Martínez-Glez; Maria Valencia; José A Caparrós-Martín; Mona Aglan; Samia Temtamy; Jair Tenorio; Veronica Pulido; Uschi Lindert; Marianne Rohrbach; David Eyre; Cecilia Giunta; Pablo Lapunzina; Victor L Ruiz-Perez
Journal:  Hum Mutat       Date:  2011-11-30       Impact factor: 4.878

10.  COL1A1 C-propeptide mutations cause ER mislocalization of procollagen and impair C-terminal procollagen processing.

Authors:  Aileen M Barnes; Aarthi Ashok; Elena N Makareeva; Marina Brusel; Wayne A Cabral; MaryAnn Weis; Catherine Moali; Emmanuel Bettler; David R Eyre; John P Cassella; Sergey Leikin; David J S Hulmes; Efrat Kessler; Joan C Marini
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-05-02       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.